ADVM Overview

Eli Lilly's Acquisition: Eli Lilly has completed its acquisition of Adverum Biotechnologies, gaining the gene therapy candidate Ixo-vec for treating wet age-related macular degeneration.

Financial Details: Lilly is paying $3.56 in cash per Adverum share, with a potential total value of $12.47 per share if certain milestones are achieved.

Adverum's Pipeline: Adverum has candidates in phase 1 for retinitis pigmentosa and Friedreich's ataxia, expanding Lilly's portfolio in gene therapy.

Market Developments: Eli Lilly's drugs, including Jaypirca, have shown success in trials and have been added to China's state insurance list, indicating a growing market presence.

Eli Lilly's Stock Performance: Eli Lilly's stock reached over $1000 per share for the first time, driven by the success of its GLP-1 drugs, Mounjaro and Zepbound, and is approaching a $1 trillion market cap.

New Drug Approvals and Revenue Growth: The company has gained approvals for several new drugs, including Omvoh and Jaypirca, contributing significantly to revenue growth, with expectations for continued sales increases from these products in 2026.

M&A Strategy for Long-Term Growth: To diversify its portfolio beyond GLP-1 drugs, Lilly is pursuing mergers and acquisitions, including the recent agreement to acquire Adverum Biotechnologies, which will enhance its pipeline with gene therapies.

Competitive Landscape and Valuation: While Lilly's stock has outperformed the industry, it is considered expensive based on its price/earnings ratio, and analysts have raised earnings estimates for 2025 and 2026, indicating positive market sentiment.

Investigation of Companies: Halper Sadeh LLC is investigating Barinthus Biotherapeutics, Fifth Third Bancorp, Adverum Biotechnologies, and Huntington Bancshares for potential violations of federal securities laws and breaches of fiduciary duties to shareholders related to their mergers and acquisitions.

Shareholder Rights: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to learn about their legal rights and options, as there may be limited time to enforce these rights.

Compensation Structure: The law firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

Legal Support for Investors: Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to recover funds and implement corporate reforms.

Investigation of Companies: Halper Sadeh LLC is investigating Comerica Incorporated, Adverum Biotechnologies, and Anywhere Real Estate for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed sales.

Comerica Sale Details: Comerica is set to be sold to Fifth Third Bancorp, with shareholders receiving 1.8663 shares of Fifth Third for each Comerica share, resulting in them owning approximately 27% of the combined company.

Adverum Sale Details: Adverum Biotechnologies will be sold to Eli Lilly, offering shareholders $3.56 per share in cash plus a contingent value right that could yield up to an additional $8.91 based on certain milestones.

Legal Support for Shareholders: Halper Sadeh LLC offers free consultations for shareholders to discuss their rights and options, emphasizing that they operate on a contingent fee basis, meaning no upfront legal fees are required.